Sylvia Hu

2.2k total citations · 1 hit paper
26 papers, 1.1k citations indexed

About

Sylvia Hu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sylvia Hu has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Sylvia Hu's work include Cancer Immunotherapy and Biomarkers (8 papers), Cancer Genomics and Diagnostics (7 papers) and Hepatitis C virus research (7 papers). Sylvia Hu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Cancer Genomics and Diagnostics (7 papers) and Hepatitis C virus research (7 papers). Sylvia Hu collaborates with scholars based in United States, Switzerland and Canada. Sylvia Hu's co-authors include K. Rajender Reddy, William M. Cassidy, Charles D. Howell, Lennox J. Jeffers, Dennis S. Charney, J. Douglas Bremner, Ann M. Rasmusson, Deborah S. Lipschitz, Steven M. Southwick and Sheila Wang and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Sylvia Hu

25 papers receiving 1.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening

2024 163 citations Daniel C. Chung, Darrell M. Gray et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sylvia Hu United States	13	483	389	322	302	209	26	1.1k
Jianhui Wu China	14	333 0.7×	301 0.8×	29 0.1×	52 0.2×	51 0.2×	69	611
Ernst Rücklinger Austria	13	243 0.5×	234 0.6×	65 0.2×	42 0.1×	177 0.8×	14	868
Jihyun Kwon South Korea	13	200 0.4×	186 0.5×	41 0.1×	52 0.2×	80 0.4×	51	578
Clizia Zichi Italy	12	140 0.3×	140 0.4×	24 0.1×	19 0.1×	47 0.2×	38	432
Fiona Day Australia	14	187 0.4×	100 0.3×	95 0.3×	137 0.5×	76 0.4×	39	618
Carissa Chu United States	15	137 0.3×	161 0.4×	38 0.1×	112 0.4×	58 0.3×	45	891
Quenten Walker Australia	14	178 0.4×	396 1.0×	28 0.1×	36 0.1×	35 0.2×	23	774
Yize Mao China	16	537 1.1×	123 0.3×	38 0.1×	74 0.2×	113 0.5×	40	874
Mai‐Yee Luk China	12	229 0.5×	105 0.3×	89 0.3×	46 0.2×	73 0.3×	28	465
Robert Lehr United States	6	86 0.2×	89 0.2×	535 1.7×	268 0.9×	105 0.5×	9	765

Countries citing papers authored by Sylvia Hu

Since Specialization

Citations

This map shows the geographic impact of Sylvia Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvia Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvia Hu more than expected).

Fields of papers citing papers by Sylvia Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvia Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvia Hu. The network helps show where Sylvia Hu may publish in the future.

Co-authorship network of co-authors of Sylvia Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvia Hu. A scholar is included among the top collaborators of Sylvia Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvia Hu. Sylvia Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Jin, Yanling, et al.. (2024). Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort. Cancer Medicine. 13(16). e70032–e70032. 1 indexed citations

2.

Chung, Daniel C., Darrell M. Gray, Joel K. Greenson, et al.. (2023). 913e CLINICAL VALIDATION OF A CELL-FREE DNA BLOOD-BASED TEST FOR COLORECTAL CANCER SCREENING IN AN AVERAGE RISK POPULATION. Gastroenterology. 164(6). S–1573. 6 indexed citations

3.

Kim, Edward S., Vamsidhar Velcheti, Tarek Mekhail, et al.. (2022). Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nature Medicine. 28(5). 939–945. 111 indexed citations

4.

Socinski, Mark A., Sarah Paul, Cindy Yun, et al.. (2019). Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC. Cancer Research. 79(13_Supplement). CT194–CT194. 7 indexed citations

5.

Gadgeel, Shirish M., Rimas V. Lukas, Jerome H. Goldschmidt, et al.. (2018). Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer. 128. 105–112. 132 indexed citations

6.

Velcheti, Vamsidhar, Tarek Mekhail, Ticiana Leal, et al.. (2018). Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). Annals of Oncology. 29. viii744–viii744. 47 indexed citations

7.

Velcheti, Vamsidhar, Edward S. Kim, Tarek Mekhail, et al.. (2018). Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.. Journal of Clinical Oncology. 36(15_suppl). 12001–12001. 34 indexed citations

8.

Mok, Tony, Shirish M. Gadgeel, Vamsidhar Velcheti, et al.. (2017). Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC. Annals of Oncology. 28. v494–v495. 12 indexed citations

9.

Lukas, Rimas V., et al.. (2017). P2.03b-014 Atezolizumab in Advanced NSCLC Patients with Baseline Brain Metastases: A Pooled Cohort Safety Analysis. Journal of Thoracic Oncology. 12(1). S941–S942. 3 indexed citations

10.

Lukas, Rimas V., et al.. (2017). Safety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases. Annals of Oncology. 28. ii28–ii28. 24 indexed citations

11.

Socinski, Mark A., Shaker R. Dakhil, Joseph L. Leach, et al.. (2016). PS01.54: Evaluation of Novel Blood-Based Biomarkers with Atezolizumab Monotherapy in 1L Advanced or Metastatic NSCLC (B-F1RST). Journal of Thoracic Oncology. 11(11). S303–S304. 2 indexed citations

12.

Hurwitz, Herbert I., Edith P. Mitchell, Thomas H. Cartwright, et al.. (2012). A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard). The Oncologist. 17(7). 937–946. 11 indexed citations

13.

Olulade, Olumide A., et al.. (2011). Assessment of temporal state-dependent interactions between auditory fMRI responses to desired and undesired acoustic sources. Hearing Research. 277(1-2). 67–77. 9 indexed citations

14.

Howell, Charles D., et al.. (2006). Peginterferon alfa‐2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. Journal of Viral Hepatitis. 13(6). 371–376. 16 indexed citations

15.

Jeffers, Lennox J., William M. Cassidy, Charles D. Howell, Sylvia Hu, & K. Rajender Reddy. (2004). Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 39(6). 1702–1708. 203 indexed citations

16.

Jeffers, Lennox J., William M. Cassidy, Charles D. Howell, Sylvia Hu, & K. Rajender Reddy. (2004). Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 40(3). 761–761. 1 indexed citations

17.

Perrillo, Robert, Kenneth D. Rothstein, Raymond A. Rubin, et al.. (2004). Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis. 11(2). 157–165. 43 indexed citations

18.

Schwarz, Kathleen B., Parvathi Mohan, Michael R. Narkewicz, et al.. (2003). The safety, efficacy and pharmacokinetics of peginterferon Alfa-2a (40KD) in children with chronic hepatitis C. Gastroenterology. 124(4). A700–A700. 17 indexed citations

19.

Cheng, Pin‐Nan, et al.. (2002). Clinical comparison of high-dose interferon-α2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C. Digestive and Liver Disease. 34(12). 851–856. 3 indexed citations

20.

Rasmusson, Ann M., Deborah S. Lipschitz, Sheila Wang, et al.. (2001). Increased pituitary and adrenal reactivity in premenopausal women with posttraumatic stress disorder. Biological Psychiatry. 50(12). 965–977. 147 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact